Patents by Inventor John Ridden

John Ridden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180193281
    Abstract: The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.
    Type: Application
    Filed: July 6, 2016
    Publication date: July 12, 2018
    Inventors: John Ridden, Christine Caroline Ridden, David Cook
  • Publication number: 20160206567
    Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.
    Type: Application
    Filed: September 25, 2014
    Publication date: July 21, 2016
    Inventors: John RIDDEN, Michael DAVIES, Liam GOOD
  • Publication number: 20160193281
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Application
    Filed: August 15, 2014
    Publication date: July 7, 2016
    Inventor: John Ridden
  • Publication number: 20160089393
    Abstract: The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2.
    Type: Application
    Filed: April 17, 2014
    Publication date: March 31, 2016
    Inventors: John Ridden, Liam Good
  • Publication number: 20050106638
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: August 30, 2004
    Publication date: May 19, 2005
    Applicant: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Phillips, John Ridden
  • Patent number: 6794192
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
  • Publication number: 20030040041
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: June 28, 2001
    Publication date: February 27, 2003
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden